Home›Legal›Semaglutide in Florida
Semaglutide in Florida: Legal Status & Provider Guide (2026)
Quick Answer
Semaglutide is a prescription substance in the United States. Semaglutide is an FDA-approved drug. Compounded versions were temporarily permitted during a drug shortage that ended in early 2025. Current federal law generally prohibits 503A/503B compounding of semaglutide except for narrow clinical exceptions. Patients should verify their provider's legal basis for offering compounded semaglutide. In Florida, compounding is governed by the Florida Board of Pharmacy (FBP). In Florida, advanced practice registered nurses (APRNs) with prescriptive authority and physician assistants may prescribe compounded peptides within the scope of their collaborative agreement. Florida's telehealth laws permit prescribing without prior in-person visit in many contexts, which has made Florida a hub for telehealth peptide programs. Prescribers must hold a Florida license to prescribe to Florida patients.
Federal Legal Status
FDA Approval Status
FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral, type 2 diabetes, 2019). Compounded semaglutide was permitted during shortage but FDA declared shortage resolved in March 2025.
Compounding Pharmacy Rules (Federal)
Compounding of semaglutide was broadly permitted under shortage exemptions through early 2025. Following FDA's March 2025 shortage resolution declaration, 503B outsourcing facilities had a wind-down period through April 2025, and 503A pharmacies through May 2025. As of mid-2025, compounded semaglutide is generally prohibited except for specific patient needs (e.g., documented allergy to an inactive ingredient in the commercially available product) under a valid prescription.
Also Known As
Ozempic · Wegovy · Rybelsus
Primary Research Areas
- Weight management
- Type 2 diabetes
- Cardiovascular risk reduction
- Metabolic health
Florida Pharmacy Board & Compounding Rules
Regulator
Compounding Overview
Florida has a large and active compounding pharmacy sector. The Florida Board of Pharmacy (Department of Health) regulates sterile and non-sterile compounding, requiring separate permits for each type. Florida pharmacies that compound sterile preparations must comply with USP 797 and undergo periodic inspections. Florida has specific rules for "office use" compounding — a provision that allows prescribers to order pre-mixed sterile compounds for use in their offices, which is relevant to many peptide clinics.
Notable Rules
- Florida requires separate permits for sterile and non-sterile compounding.
- Florida allows "office use" compounding with specific restrictions — relevant to many peptide clinical practices.
- USP 797 compliance is mandatory for all sterile compounding facilities.
- Florida telehealth laws are permissive by national standards, making the state a major market for telehealth peptide programs.
- Out-of-state pharmacies must be registered with the Florida Board of Pharmacy to ship into the state.
Prescribing Requirements in Florida
In Florida, advanced practice registered nurses (APRNs) with prescriptive authority and physician assistants may prescribe compounded peptides within the scope of their collaborative agreement. Florida's telehealth laws permit prescribing without prior in-person visit in many contexts, which has made Florida a hub for telehealth peptide programs. Prescribers must hold a Florida license to prescribe to Florida patients.
About Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed by Novo Nordisk. It is FDA-approved for type 2 diabetes and chronic weight management and is among the most studied compounds in contemporary metabolic medicine.
For more research information, mechanism of action, and provider availability, see the Semaglutide research profile on PeptideBase.
Frequently Asked Questions
- Is compounded semaglutide legal in 2026?
- FDA declared the semaglutide shortage resolved in March 2025. After wind-down periods, compounding of semaglutide is generally prohibited for 503A and 503B facilities. Narrow exceptions exist for documented allergies to commercially available formulations. Patients should ask providers for the specific legal basis for any compounded product.
- What is the difference between Ozempic, Wegovy, and compounded semaglutide?
- Ozempic (0.5–2 mg weekly injection) is approved for type 2 diabetes. Wegovy (2.4 mg weekly injection) is approved for chronic weight management. Compounded semaglutide was chemically equivalent but manufactured by compounding pharmacies — a practice now restricted following the shortage resolution.
Semaglutide Providers in Florida
No providers currently listed in Florida for Semaglutide. Browse the full directory to find providers offering Semaglutide.
Browse all Semaglutide providers →Semaglutide Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare Semaglutide legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .